#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=6. Angiogenesis in Glioblastomas
1-1	0-2	6.	_	_	_	_
1-2	3-15	Angiogenesis	abstract[1]	new[1]	coref	2-14[8_1]
1-3	16-18	in	abstract[1]	new[1]	_	_
1-4	19-32	Glioblastomas	abstract[1]|abstract	new[1]|new	coref	2-3

#Text=Features of glioblastomas are a high propensity to invade the surrounding tissues and extensive angiogenesis .
2-1	33-41	Features	abstract[3]	new[3]	coref	2-5[5_3]
2-2	42-44	of	abstract[3]	new[3]	_	_
2-3	45-58	glioblastomas	abstract[3]|abstract	new[3]|giv	coref	8-11
2-4	59-62	are	_	_	_	_
2-5	63-64	a	abstract[5]	giv[5]	_	_
2-6	65-69	high	abstract[5]	giv[5]	_	_
2-7	70-80	propensity	abstract[5]	giv[5]	_	_
2-8	81-83	to	abstract[5]	giv[5]	_	_
2-9	84-90	invade	abstract[5]	giv[5]	_	_
2-10	91-94	the	abstract[5]|object[6]|abstract[7]	giv[5]|new[6]|new[7]	ana	3-1[0_7]
2-11	95-106	surrounding	abstract[5]|object[6]|abstract[7]	giv[5]|new[6]|new[7]	_	_
2-12	107-114	tissues	abstract[5]|object[6]|abstract[7]	giv[5]|new[6]|new[7]	_	_
2-13	115-118	and	abstract[5]|abstract[7]	giv[5]|new[7]	_	_
2-14	119-128	extensive	abstract[5]|abstract[7]|abstract[8]	giv[5]|new[7]|giv[8]	coref	5-1[26_8]
2-15	129-141	angiogenesis	abstract[5]|abstract[7]|abstract[8]	giv[5]|new[7]|giv[8]	_	_
2-16	142-143	.	_	_	_	_

#Text=They are characterized by a pathological vascular system with a dense network of winding vessels of different diameters , increased permeability , and with abnormally thickened basement membranes .
3-1	144-148	They	abstract	giv	coref	30-17[205_0]
3-2	149-152	are	_	_	_	_
3-3	153-166	characterized	_	_	_	_
3-4	167-169	by	_	_	_	_
3-5	170-171	a	place[10]	new[10]	_	_
3-6	172-184	pathological	place[10]	new[10]	_	_
3-7	185-193	vascular	place[10]	new[10]	_	_
3-8	194-200	system	place[10]	new[10]	_	_
3-9	201-205	with	place[10]	new[10]	_	_
3-10	206-207	a	place[10]|abstract[11]	new[10]|new[11]	coref	12-12[91_11]
3-11	208-213	dense	place[10]|abstract[11]	new[10]|new[11]	_	_
3-12	214-221	network	place[10]|abstract[11]	new[10]|new[11]	_	_
3-13	222-224	of	place[10]|abstract[11]	new[10]|new[11]	_	_
3-14	225-232	winding	place[10]|abstract[11]|object[12]	new[10]|new[11]|new[12]	coref	5-15[31_12]
3-15	233-240	vessels	place[10]|abstract[11]|object[12]	new[10]|new[11]|new[12]	_	_
3-16	241-243	of	place[10]|abstract[11]|object[12]	new[10]|new[11]|new[12]	_	_
3-17	244-253	different	place[10]|abstract[11]|object[12]|abstract[13]	new[10]|new[11]|new[12]|new[13]	_	_
3-18	254-263	diameters	place[10]|abstract[11]|object[12]|abstract[13]	new[10]|new[11]|new[12]|new[13]	_	_
3-19	264-265	,	place[10]|abstract[11]|object[12]	new[10]|new[11]|new[12]	_	_
3-20	266-275	increased	place[10]|abstract[11]|object[12]|substance[14]	new[10]|new[11]|new[12]|new[14]	_	_
3-21	276-288	permeability	place[10]|abstract[11]|object[12]|substance[14]	new[10]|new[11]|new[12]|new[14]	_	_
3-22	289-290	,	place[10]	new[10]	_	_
3-23	291-294	and	place[10]	new[10]	_	_
3-24	295-299	with	place[10]	new[10]	_	_
3-25	300-310	abnormally	place[10]|object[16]	new[10]|new[16]	_	_
3-26	311-320	thickened	place[10]|object[16]	new[10]|new[16]	_	_
3-27	321-329	basement	place[10]|place|object[16]	new[10]|new|new[16]	coref	7-26
3-28	330-339	membranes	place[10]|object[16]	new[10]|new[16]	_	_
3-29	340-341	.	_	_	_	_

#Text=These properties are often the cause of relapses and therapy failures because they hinder tumor access to cytotoxic chemotherapy .
4-1	342-347	These	abstract[17]	new[17]	coref	4-4[18_17]
4-2	348-358	properties	abstract[17]	new[17]	_	_
4-3	359-362	are	_	_	_	_
4-4	363-368	often	abstract[18]	giv[18]	ana	4-13[0_18]
4-5	369-372	the	abstract[18]	giv[18]	_	_
4-6	373-378	cause	abstract[18]	giv[18]	_	_
4-7	379-381	of	abstract[18]	giv[18]	_	_
4-8	382-390	relapses	abstract[18]|event	giv[18]|new	_	_
4-9	391-394	and	abstract[18]	giv[18]	_	_
4-10	395-402	therapy	abstract[18]|abstract|event[21]	giv[18]|new|new[21]	_	_
4-11	403-411	failures	abstract[18]|event[21]	giv[18]|new[21]	_	_
4-12	412-419	because	_	_	_	_
4-13	420-424	they	abstract	giv	_	_
4-14	425-431	hinder	_	_	_	_
4-15	432-437	tumor	object|event[24]	new|new[24]	coref	5-7[28_0]
4-16	438-444	access	event[24]	new[24]	_	_
4-17	445-447	to	event[24]	new[24]	_	_
4-18	448-457	cytotoxic	event[24]|abstract[25]	new[24]|new[25]	_	_
4-19	458-470	chemotherapy	event[24]|abstract[25]	new[24]|new[25]	_	_
4-20	471-472	.	_	_	_	_

#Text=Angiogenesis caused by the presence of a tumor is defined as the formation of new blood vessels based on existing ones , which can be visualized using ultra-high-field magnetic resonance angiography .
5-1	473-485	Angiogenesis	abstract[26]	giv[26]	coref	8-9[55_26]
5-2	486-492	caused	abstract[26]	giv[26]	_	_
5-3	493-495	by	abstract[26]	giv[26]	_	_
5-4	496-499	the	abstract[26]|abstract[27]	giv[26]|new[27]	_	_
5-5	500-508	presence	abstract[26]|abstract[27]	giv[26]|new[27]	_	_
5-6	509-511	of	abstract[26]|abstract[27]	giv[26]|new[27]	_	_
5-7	512-513	a	abstract[26]|abstract[27]|object[28]	giv[26]|new[27]|giv[28]	coref	8-16[0_28]
5-8	514-519	tumor	abstract[26]|abstract[27]|object[28]	giv[26]|new[27]|giv[28]	_	_
5-9	520-522	is	_	_	_	_
5-10	523-530	defined	_	_	_	_
5-11	531-533	as	_	_	_	_
5-12	534-537	the	event[29]	new[29]	_	_
5-13	538-547	formation	event[29]	new[29]	_	_
5-14	548-550	of	event[29]	new[29]	_	_
5-15	551-554	new	event[29]|object[31]	new[29]|giv[31]	coref	7-42[52_31]
5-16	555-560	blood	event[29]|substance|object[31]	new[29]|new|giv[31]	coref	7-42
5-17	561-568	vessels	event[29]|object[31]	new[29]|giv[31]	_	_
5-18	569-574	based	event[29]|object[31]	new[29]|giv[31]	_	_
5-19	575-577	on	event[29]|object[31]	new[29]|giv[31]	_	_
5-20	578-586	existing	event[29]|object[31]|object[32]	new[29]|giv[31]|new[32]	_	_
5-21	587-591	ones	event[29]|object[31]|object[32]	new[29]|giv[31]|new[32]	_	_
5-22	592-593	,	event[29]|object[31]	new[29]|giv[31]	_	_
5-23	594-599	which	event[29]|object[31]	new[29]|giv[31]	_	_
5-24	600-603	can	event[29]|object[31]	new[29]|giv[31]	_	_
5-25	604-606	be	event[29]|object[31]	new[29]|giv[31]	_	_
5-26	607-617	visualized	event[29]|object[31]	new[29]|giv[31]	_	_
5-27	618-623	using	event[29]|object[31]	new[29]|giv[31]	_	_
5-28	624-640	ultra-high-field	event[29]|object[31]|abstract[34]	new[29]|giv[31]|new[34]	_	_
5-29	641-649	magnetic	event[29]|object[31]|abstract[33]|abstract[34]	new[29]|giv[31]|new[33]|new[34]	_	_
5-30	650-659	resonance	event[29]|object[31]|abstract[33]|abstract[34]	new[29]|giv[31]|new[33]|new[34]	_	_
5-31	660-671	angiography	event[29]|object[31]|abstract[34]	new[29]|giv[31]|new[34]	_	_
5-32	672-673	.	_	_	_	_

#Text=The mechanism of this process is very complex .
6-1	674-677	The	abstract[35]	new[35]	coref	15-9[105_35]
6-2	678-687	mechanism	abstract[35]	new[35]	_	_
6-3	688-690	of	abstract[35]	new[35]	_	_
6-4	691-695	this	abstract[35]|event[36]	new[35]|new[36]	_	_
6-5	696-703	process	abstract[35]|event[36]	new[35]|new[36]	_	_
6-6	704-706	is	_	_	_	_
6-7	707-711	very	_	_	_	_
6-8	712-719	complex	_	_	_	_
6-9	720-721	.	_	_	_	_

#Text=In GBM , the development of pathological vasculature is based on changes in adhesion molecules on the endothelial surface , the presence of an erratic basement membrane , a decrease in pericyte coverage , and a weaker binding of astrocytes to blood vessels .
7-1	722-724	In	_	_	_	_
7-2	725-728	GBM	abstract	new	coref	27-15
7-3	729-730	,	_	_	_	_
7-4	731-734	the	event[38]	new[38]	_	_
7-5	735-746	development	event[38]	new[38]	_	_
7-6	747-749	of	event[38]	new[38]	_	_
7-7	750-762	pathological	event[38]|object[39]	new[38]|new[39]	_	_
7-8	763-774	vasculature	event[38]|object[39]	new[38]|new[39]	_	_
7-9	775-777	is	_	_	_	_
7-10	778-783	based	_	_	_	_
7-11	784-786	on	_	_	_	_
7-12	787-794	changes	event[40]	new[40]	_	_
7-13	795-797	in	event[40]	new[40]	_	_
7-14	798-806	adhesion	event[40]|substance|substance[42]	new[40]|new|new[42]	_	_
7-15	807-816	molecules	event[40]|substance[42]	new[40]|new[42]	_	_
7-16	817-819	on	event[40]|substance[42]	new[40]|new[42]	_	_
7-17	820-823	the	event[40]|substance[42]|place[43]	new[40]|new[42]|new[43]	_	_
7-18	824-835	endothelial	event[40]|substance[42]|place[43]	new[40]|new[42]|new[43]	_	_
7-19	836-843	surface	event[40]|substance[42]|place[43]	new[40]|new[42]|new[43]	_	_
7-20	844-845	,	_	_	_	_
7-21	846-849	the	abstract[44]	new[44]	_	_
7-22	850-858	presence	abstract[44]	new[44]	_	_
7-23	859-861	of	abstract[44]	new[44]	_	_
7-24	862-864	an	abstract[44]|place[46]	new[44]|new[46]	_	_
7-25	865-872	erratic	abstract[44]|place[46]	new[44]|new[46]	_	_
7-26	873-881	basement	abstract[44]|place|place[46]	new[44]|giv|new[46]	_	_
7-27	882-890	membrane	abstract[44]|place[46]	new[44]|new[46]	_	_
7-28	891-892	,	_	_	_	_
7-29	893-894	a	event[47]	new[47]	_	_
7-30	895-903	decrease	event[47]	new[47]	_	_
7-31	904-906	in	event[47]	new[47]	_	_
7-32	907-915	pericyte	event[47]|abstract[48]	new[47]|new[48]	_	_
7-33	916-924	coverage	event[47]|abstract[48]	new[47]|new[48]	_	_
7-34	925-926	,	_	_	_	_
7-35	927-930	and	_	_	_	_
7-36	931-932	a	event[49]	new[49]	_	_
7-37	933-939	weaker	event[49]	new[49]	_	_
7-38	940-947	binding	event[49]	new[49]	_	_
7-39	948-950	of	event[49]	new[49]	_	_
7-40	951-961	astrocytes	event[49]|abstract	new[49]|new	_	_
7-41	962-964	to	event[49]	new[49]	_	_
7-42	965-970	blood	event[49]|substance|object[52]	new[49]|giv|giv[52]	coref|coref	8-32|8-32[66_52]
7-43	971-978	vessels	event[49]|object[52]	new[49]|giv[52]	_	_
7-44	979-980	.	_	_	_	_

#Text=A common element for the large invasiveness and angiogenesis of glioblastomas is the loss of tumor cell boundaries with the surrounding microenvironment consisting of brain tissue , subarachnoid space , and blood vessels .
8-1	981-982	A	event[53]	new[53]	coref	8-13[57_53]
8-2	983-989	common	event[53]	new[53]	_	_
8-3	990-997	element	event[53]	new[53]	_	_
8-4	998-1001	for	event[53]	new[53]	_	_
8-5	1002-1005	the	event[53]|abstract[54]	new[53]|new[54]	coref	25-14[0_54]
8-6	1006-1011	large	event[53]|abstract[54]	new[53]|new[54]	_	_
8-7	1012-1024	invasiveness	event[53]|abstract[54]	new[53]|new[54]	_	_
8-8	1025-1028	and	event[53]	new[53]	_	_
8-9	1029-1041	angiogenesis	event[53]|abstract[55]	new[53]|giv[55]	coref	9-1[0_55]
8-10	1042-1044	of	event[53]|abstract[55]	new[53]|giv[55]	_	_
8-11	1045-1058	glioblastomas	event[53]|abstract[55]|abstract	new[53]|giv[55]|giv	_	_
8-12	1059-1061	is	_	_	_	_
8-13	1062-1065	the	event[57]	giv[57]	_	_
8-14	1066-1070	loss	event[57]	giv[57]	_	_
8-15	1071-1073	of	event[57]	giv[57]	_	_
8-16	1074-1079	tumor	event[57]|object|abstract[60]	giv[57]|giv|new[60]	coref	25-3
8-17	1080-1084	cell	event[57]|place|abstract[60]	giv[57]|new|new[60]	coref	14-12
8-18	1085-1095	boundaries	event[57]|abstract[60]	giv[57]|new[60]	_	_
8-19	1096-1100	with	event[57]|abstract[60]	giv[57]|new[60]	_	_
8-20	1101-1104	the	event[57]|abstract[60]|abstract[61]	giv[57]|new[60]|new[61]	coref	28-17[183_61]
8-21	1105-1116	surrounding	event[57]|abstract[60]|abstract[61]	giv[57]|new[60]|new[61]	_	_
8-22	1117-1133	microenvironment	event[57]|abstract[60]|abstract[61]	giv[57]|new[60]|new[61]	_	_
8-23	1134-1144	consisting	event[57]|abstract[60]|abstract[61]	giv[57]|new[60]|new[61]	_	_
8-24	1145-1147	of	event[57]|abstract[60]|abstract[61]	giv[57]|new[60]|new[61]	_	_
8-25	1148-1153	brain	event[57]|abstract[60]|abstract[61]|object|object[63]	giv[57]|new[60]|new[61]|new|new[63]	_	_
8-26	1154-1160	tissue	event[57]|abstract[60]|abstract[61]|object[63]	giv[57]|new[60]|new[61]|new[63]	_	_
8-27	1161-1162	,	event[57]|abstract[60]|abstract[61]	giv[57]|new[60]|new[61]	_	_
8-28	1163-1175	subarachnoid	event[57]|abstract[60]|abstract[61]|place[64]	giv[57]|new[60]|new[61]|new[64]	_	_
8-29	1176-1181	space	event[57]|abstract[60]|abstract[61]|place[64]	giv[57]|new[60]|new[61]|new[64]	_	_
8-30	1182-1183	,	event[57]|abstract[60]|abstract[61]	giv[57]|new[60]|new[61]	_	_
8-31	1184-1187	and	event[57]|abstract[60]|abstract[61]	giv[57]|new[60]|new[61]	_	_
8-32	1188-1193	blood	event[57]|abstract[60]|abstract[61]|substance|object[66]	giv[57]|new[60]|new[61]|giv|giv[66]	_	_
8-33	1194-1201	vessels	event[57]|abstract[60]|abstract[61]|object[66]	giv[57]|new[60]|new[61]|giv[66]	_	_
8-34	1202-1203	.	_	_	_	_

#Text=Angiogenesis occurs under the influence of various mechanisms , which we divide into hypoxia-dependent and hypoxia-independent .
9-1	1204-1216	Angiogenesis	abstract	giv	coref	13-15
9-2	1217-1223	occurs	_	_	_	_
9-3	1224-1229	under	_	_	_	_
9-4	1230-1233	the	abstract[68]	new[68]	_	_
9-5	1234-1243	influence	abstract[68]	new[68]	_	_
9-6	1244-1246	of	abstract[68]	new[68]	_	_
9-7	1247-1254	various	abstract[68]|abstract[69]	new[68]|new[69]	_	_
9-8	1255-1265	mechanisms	abstract[68]|abstract[69]	new[68]|new[69]	_	_
9-9	1266-1267	,	abstract[68]|abstract[69]	new[68]|new[69]	_	_
9-10	1268-1273	which	abstract[68]|abstract[69]	new[68]|new[69]	_	_
9-11	1274-1276	we	abstract[68]|abstract[69]|person	new[68]|new[69]|acc	_	_
9-12	1277-1283	divide	abstract[68]|abstract[69]	new[68]|new[69]	_	_
9-13	1284-1288	into	abstract[68]|abstract[69]	new[68]|new[69]	_	_
9-14	1289-1306	hypoxia-dependent	abstract[68]|abstract[69]	new[68]|new[69]	_	_
9-15	1307-1310	and	abstract[68]|abstract[69]	new[68]|new[69]	_	_
9-16	1311-1330	hypoxia-independent	abstract[68]|abstract[69]|abstract	new[68]|new[69]|new	_	_
9-17	1331-1332	.	_	_	_	_

#Text=Hypoxia has been proven to inactivate prolyl hydroxylases .
10-1	1333-1340	Hypoxia	abstract	new	ana	11-1
10-2	1341-1344	has	_	_	_	_
10-3	1345-1349	been	_	_	_	_
10-4	1350-1356	proven	_	_	_	_
10-5	1357-1359	to	_	_	_	_
10-6	1360-1370	inactivate	_	_	_	_
10-7	1371-1377	prolyl	abstract|substance[74]	new|new[74]	_	_
10-8	1378-1390	hydroxylases	substance[74]	new[74]	_	_
10-9	1391-1392	.	_	_	_	_

#Text=This increases the level of hypoxia-inducible factor-1α ( HIF-1α ) , causing the release of vascular endothelial growth factor ( VEGF ) by glioma cells affected by hypoxia .
11-1	1393-1397	This	abstract	giv	coref	11-28
11-2	1398-1407	increases	_	_	_	_
11-3	1408-1411	the	abstract[76]	new[76]	_	_
11-4	1412-1417	level	abstract[76]	new[76]	_	_
11-5	1418-1420	of	abstract[76]	new[76]	_	_
11-6	1421-1438	hypoxia-inducible	abstract[76]|substance[77]	new[76]|new[77]	_	_
11-7	1439-1448	factor-1α	abstract[76]|substance[77]	new[76]|new[77]	_	_
11-8	1449-1450	(	_	_	_	_
11-9	1451-1457	HIF-1α	abstract	new	_	_
11-10	1458-1459	)	_	_	_	_
11-11	1460-1461	,	_	_	_	_
11-12	1462-1469	causing	_	_	_	_
11-13	1470-1473	the	event[79]	new[79]	_	_
11-14	1474-1481	release	event[79]	new[79]	_	_
11-15	1482-1484	of	event[79]	new[79]	_	_
11-16	1485-1493	vascular	event[79]|substance[82]	new[79]|new[82]	coref	13-10[95_82]
11-17	1494-1505	endothelial	event[79]|abstract|substance[82]	new[79]|new|new[82]	_	_
11-18	1506-1512	growth	event[79]|abstract|substance[82]	new[79]|new|new[82]	coref	12-12[92_0]
11-19	1513-1519	factor	event[79]|substance[82]	new[79]|new[82]	_	_
11-20	1520-1521	(	event[79]	new[79]	_	_
11-21	1522-1526	VEGF	event[79]|abstract	new[79]|new	coref	12-4
11-22	1527-1528	)	event[79]	new[79]	_	_
11-23	1529-1531	by	event[79]	new[79]	_	_
11-24	1532-1538	glioma	event[79]|abstract|animal[85]	new[79]|new|new[85]	coref	19-17[134_0]
11-25	1539-1544	cells	event[79]|animal[85]	new[79]|new[85]	_	_
11-26	1545-1553	affected	event[79]|animal[85]	new[79]|new[85]	_	_
11-27	1554-1556	by	event[79]|animal[85]	new[79]|new[85]	_	_
11-28	1557-1564	hypoxia	event[79]|animal[85]|abstract	new[79]|new[85]|giv	coref	13-6
11-29	1565-1566	.	_	_	_	_

#Text=The task of VEGF is to counteract oxygen deficiency by inducing vascular network growth .
12-1	1567-1570	The	abstract[87]	new[87]	_	_
12-2	1571-1575	task	abstract[87]	new[87]	_	_
12-3	1576-1578	of	abstract[87]	new[87]	_	_
12-4	1579-1583	VEGF	abstract[87]|abstract	new[87]|giv	coref	15-3
12-5	1584-1586	is	_	_	_	_
12-6	1587-1589	to	_	_	_	_
12-7	1590-1600	counteract	_	_	_	_
12-8	1601-1607	oxygen	substance|abstract[90]	new|new[90]	_	_
12-9	1608-1618	deficiency	abstract[90]	new[90]	_	_
12-10	1619-1621	by	_	_	_	_
12-11	1622-1630	inducing	_	_	_	_
12-12	1631-1639	vascular	abstract[91]|abstract[92]	giv[91]|giv[92]	coref	28-3[177_92]
12-13	1640-1647	network	abstract[91]|abstract[92]	giv[91]|giv[92]	_	_
12-14	1648-1654	growth	abstract[92]	giv[92]	_	_
12-15	1655-1656	.	_	_	_	_

#Text=In spite of this , hypoxia may not be the only trigger factor for angiogenesis .
13-1	1657-1659	In	_	_	_	_
13-2	1660-1665	spite	_	_	_	_
13-3	1666-1668	of	_	_	_	_
13-4	1669-1673	this	_	_	_	_
13-5	1674-1675	,	_	_	_	_
13-6	1676-1683	hypoxia	abstract	giv	coref	14-12[101_0]
13-7	1684-1687	may	_	_	_	_
13-8	1688-1691	not	_	_	_	_
13-9	1692-1694	be	_	_	_	_
13-10	1695-1698	the	substance[95]	giv[95]	_	_
13-11	1699-1703	only	substance[95]	giv[95]	_	_
13-12	1704-1711	trigger	person|substance[95]	new|giv[95]	_	_
13-13	1712-1718	factor	substance[95]	giv[95]	_	_
13-14	1719-1722	for	substance[95]	giv[95]	_	_
13-15	1723-1735	angiogenesis	substance[95]|abstract	giv[95]|giv	ana	14-1
13-16	1736-1737	.	_	_	_	_

#Text=This applies particularly to the initial stages of carcinogenesis , when cell hypoxia is not yet severe .
14-1	1738-1742	This	abstract	giv	coref	17-15
14-2	1743-1750	applies	_	_	_	_
14-3	1751-1763	particularly	_	_	_	_
14-4	1764-1766	to	_	_	_	_
14-5	1767-1770	the	abstract[98]	new[98]	_	_
14-6	1771-1778	initial	abstract[98]	new[98]	_	_
14-7	1779-1785	stages	abstract[98]	new[98]	_	_
14-8	1786-1788	of	abstract[98]	new[98]	_	_
14-9	1789-1803	carcinogenesis	abstract[98]|substance	new[98]|new	_	_
14-10	1804-1805	,	_	_	_	_
14-11	1806-1810	when	_	_	_	_
14-12	1811-1815	cell	place|abstract[101]	giv|giv[101]	coref|coref	15-13[0_101]|18-24[128_0]
14-13	1816-1823	hypoxia	abstract[101]	giv[101]	_	_
14-14	1824-1826	is	_	_	_	_
14-15	1827-1830	not	_	_	_	_
14-16	1831-1834	yet	_	_	_	_
14-17	1835-1841	severe	_	_	_	_
14-18	1842-1843	.	_	_	_	_

#Text=Regulation of VEGF secretion also takes place by a mechanism independent of hypoxia , involving dysregulated activation of mitogenic and survival pathways .
15-1	1844-1854	Regulation	event[102]	new[102]	_	_
15-2	1855-1857	of	event[102]	new[102]	_	_
15-3	1858-1862	VEGF	event[102]|abstract|abstract[104]	new[102]|giv|new[104]	coref	17-13[118_0]
15-4	1863-1872	secretion	event[102]|abstract[104]	new[102]|new[104]	_	_
15-5	1873-1877	also	_	_	_	_
15-6	1878-1883	takes	_	_	_	_
15-7	1884-1889	place	_	_	_	_
15-8	1890-1892	by	_	_	_	_
15-9	1893-1894	a	abstract[105]	giv[105]	_	_
15-10	1895-1904	mechanism	abstract[105]	giv[105]	_	_
15-11	1905-1916	independent	abstract[105]	giv[105]	_	_
15-12	1917-1919	of	_	_	_	_
15-13	1920-1927	hypoxia	abstract	giv	ana	16-1
15-14	1928-1929	,	_	_	_	_
15-15	1930-1939	involving	_	_	_	_
15-16	1940-1952	dysregulated	event[107]	new[107]	_	_
15-17	1953-1963	activation	event[107]	new[107]	_	_
15-18	1964-1966	of	event[107]	new[107]	_	_
15-19	1967-1976	mitogenic	event[107]|abstract[108]	new[107]|new[108]	coref	26-11[168_108]
15-20	1977-1980	and	event[107]|abstract[108]	new[107]|new[108]	_	_
15-21	1981-1989	survival	event[107]|abstract[108]	new[107]|new[108]	_	_
15-22	1990-1998	pathways	event[107]|abstract[108]	new[107]|new[108]	_	_
15-23	1999-2000	.	_	_	_	_

#Text=This applies to phosphatidylinositol 3-kinase and Ras/mitogen-activated protein kinase .
16-1	2001-2005	This	abstract	giv	_	_
16-2	2006-2013	applies	_	_	_	_
16-3	2014-2016	to	_	_	_	_
16-4	2017-2037	phosphatidylinositol	abstract|person[111]	new|new[111]	_	_
16-5	2038-2046	3-kinase	person[111]	new[111]	_	_
16-6	2047-2050	and	_	_	_	_
16-7	2051-2072	Ras/mitogen-activated	abstract[113]	new[113]	_	_
16-8	2073-2080	protein	substance|abstract[113]	new|new[113]	_	_
16-9	2081-2087	kinase	abstract[113]	new[113]	_	_
16-10	2088-2089	.	_	_	_	_

#Text=The PD-L1/PD-1 axis may also have roles in regulating the level of VEGF mediating angiogenesis .
17-1	2090-2093	The	abstract[115]	new[115]	coref	22-20[150_115]
17-2	2094-2104	PD-L1/PD-1	object|abstract[115]	new|new[115]	_	_
17-3	2105-2109	axis	abstract[115]	new[115]	_	_
17-4	2110-2113	may	_	_	_	_
17-5	2114-2118	also	_	_	_	_
17-6	2119-2123	have	_	_	_	_
17-7	2124-2129	roles	abstract	new	_	_
17-8	2130-2132	in	_	_	_	_
17-9	2133-2143	regulating	_	_	_	_
17-10	2144-2147	the	abstract[117]	new[117]	_	_
17-11	2148-2153	level	abstract[117]	new[117]	_	_
17-12	2154-2156	of	abstract[117]	new[117]	_	_
17-13	2157-2161	VEGF	abstract[117]|abstract[118]	new[117]|giv[118]	coref	18-16[0_118]
17-14	2162-2171	mediating	abstract[117]|abstract[118]	new[117]|giv[118]	_	_
17-15	2172-2184	angiogenesis	abstract[117]|abstract[118]|abstract	new[117]|giv[118]|giv	coref	25-3[160_0]
17-16	2185-2186	.	_	_	_	_

#Text=In studies conducted by Shin et al. , a positive correlation between PDL1 levels and VEGF expression was shown in 197 patients with renal cell carcinoma .
18-1	2187-2189	In	_	_	_	_
18-2	2190-2197	studies	abstract[120]	new[120]	coref	21-4[141_120]
18-3	2198-2207	conducted	abstract[120]	new[120]	_	_
18-4	2208-2210	by	abstract[120]	new[120]	_	_
18-5	2211-2215	Shin	abstract[120]|person	new[120]|new	_	_
18-6	2216-2218	et	abstract[120]	new[120]	_	_
18-7	2219-2222	al.	abstract[120]	new[120]	_	_
18-8	2223-2224	,	_	_	_	_
18-9	2225-2226	a	abstract[122]	new[122]	_	_
18-10	2227-2235	positive	abstract[122]	new[122]	_	_
18-11	2236-2247	correlation	abstract[122]	new[122]	_	_
18-12	2248-2255	between	abstract[122]	new[122]	_	_
18-13	2256-2260	PDL1	abstract[122]|abstract|abstract[124]	new[122]|new|new[124]	coref	20-6[138_124]
18-14	2261-2267	levels	abstract[122]|abstract[124]	new[122]|new[124]	_	_
18-15	2268-2271	and	abstract[122]	new[122]	_	_
18-16	2272-2276	VEGF	abstract[122]|abstract|abstract[126]	new[122]|giv|new[126]	coref|coref	20-7[0_126]|20-12
18-17	2277-2287	expression	abstract[122]|abstract[126]	new[122]|new[126]	_	_
18-18	2288-2291	was	_	_	_	_
18-19	2292-2297	shown	_	_	_	_
18-20	2298-2300	in	_	_	_	_
18-21	2301-2304	197	person[127]	new[127]	_	_
18-22	2305-2313	patients	person[127]	new[127]	_	_
18-23	2314-2318	with	person[127]	new[127]	_	_
18-24	2319-2324	renal	person[127]|place[128]|object[129]	new[127]|giv[128]|new[129]	coref	25-11[0_128]
18-25	2325-2329	cell	person[127]|place[128]|object[129]	new[127]|giv[128]|new[129]	_	_
18-26	2330-2339	carcinoma	person[127]|object[129]	new[127]|new[129]	_	_
18-27	2340-2341	.	_	_	_	_

#Text=Similar observations were noted by Song et al. The study was conducted in 64 patients with primary glioma .
19-1	2342-2349	Similar	abstract[130]	new[130]	_	_
19-2	2350-2362	observations	abstract[130]	new[130]	_	_
19-3	2363-2367	were	_	_	_	_
19-4	2368-2373	noted	_	_	_	_
19-5	2374-2376	by	_	_	_	_
19-6	2377-2381	Song	person	new	_	_
19-7	2382-2384	et	_	_	_	_
19-8	2385-2388	al.	_	_	_	_
19-9	2389-2392	The	abstract[132]	new[132]	_	_
19-10	2393-2398	study	abstract[132]	new[132]	_	_
19-11	2399-2402	was	_	_	_	_
19-12	2403-2412	conducted	_	_	_	_
19-13	2413-2415	in	_	_	_	_
19-14	2416-2418	64	person[133]	new[133]	ana	20-3[0_133]
19-15	2419-2427	patients	person[133]	new[133]	_	_
19-16	2428-2432	with	person[133]	new[133]	_	_
19-17	2433-2440	primary	person[133]|abstract[134]	new[133]|giv[134]	_	_
19-18	2441-2447	glioma	person[133]|abstract[134]	new[133]|giv[134]	_	_
19-19	2448-2449	.	_	_	_	_

#Text=Also , they showed that PD-L1 expression levels correlated well with VEGF levels .
20-1	2450-2454	Also	_	_	_	_
20-2	2455-2456	,	_	_	_	_
20-3	2457-2461	they	person	giv	_	_
20-4	2462-2468	showed	_	_	_	_
20-5	2469-2473	that	_	_	_	_
20-6	2474-2479	PD-L1	abstract|abstract[138]	new|giv[138]	coref	20-12[140_138]
20-7	2480-2490	expression	abstract|abstract[138]	giv|giv[138]	coref	38-1[250_0]
20-8	2491-2497	levels	abstract[138]	giv[138]	_	_
20-9	2498-2508	correlated	_	_	_	_
20-10	2509-2513	well	_	_	_	_
20-11	2514-2518	with	_	_	_	_
20-12	2519-2523	VEGF	abstract|abstract[140]	giv|giv[140]	_	_
20-13	2524-2530	levels	abstract[140]	giv[140]	_	_
20-14	2531-2532	.	_	_	_	_

#Text=However , not all studies agreed on this point .
21-1	2533-2540	However	_	_	_	_
21-2	2541-2542	,	_	_	_	_
21-3	2543-2546	not	_	_	_	_
21-4	2547-2550	all	abstract[141]	giv[141]	coref	41-1[0_141]
21-5	2551-2558	studies	abstract[141]	giv[141]	_	_
21-6	2559-2565	agreed	_	_	_	_
21-7	2566-2568	on	_	_	_	_
21-8	2569-2573	this	abstract[142]	new[142]	_	_
21-9	2574-2579	point	abstract[142]	new[142]	_	_
21-10	2580-2581	.	_	_	_	_

#Text=Research by Joseph et al. indicates the existence of a negative relationship between VEGF-related genes and the activity of the PD-L1/PD1 axis .
22-1	2582-2590	Research	organization[143]	new[143]	_	_
22-2	2591-2593	by	organization[143]	new[143]	_	_
22-3	2594-2600	Joseph	organization[143]|person	new[143]|new	_	_
22-4	2601-2603	et	organization[143]	new[143]	_	_
22-5	2604-2607	al.	organization[143]	new[143]	_	_
22-6	2608-2617	indicates	_	_	_	_
22-7	2618-2621	the	abstract[145]	new[145]	_	_
22-8	2622-2631	existence	abstract[145]	new[145]	_	_
22-9	2632-2634	of	abstract[145]	new[145]	_	_
22-10	2635-2636	a	abstract[145]|abstract[146]	new[145]|new[146]	coref	23-8[153_146]
22-11	2637-2645	negative	abstract[145]|abstract[146]	new[145]|new[146]	_	_
22-12	2646-2658	relationship	abstract[145]|abstract[146]	new[145]|new[146]	_	_
22-13	2659-2666	between	abstract[145]|abstract[146]	new[145]|new[146]	_	_
22-14	2667-2679	VEGF-related	abstract[145]|abstract[146]|abstract[147]	new[145]|new[146]|new[147]	_	_
22-15	2680-2685	genes	abstract[145]|abstract[146]|abstract[147]	new[145]|new[146]|new[147]	_	_
22-16	2686-2689	and	abstract[145]|abstract[146]	new[145]|new[146]	_	_
22-17	2690-2693	the	abstract[145]|abstract[146]|abstract[148]	new[145]|new[146]|new[148]	_	_
22-18	2694-2702	activity	abstract[145]|abstract[146]|abstract[148]	new[145]|new[146]|new[148]	_	_
22-19	2703-2705	of	abstract[145]|abstract[146]|abstract[148]	new[145]|new[146]|new[148]	_	_
22-20	2706-2709	the	abstract[145]|abstract[146]|abstract[148]|abstract[150]	new[145]|new[146]|new[148]|giv[150]	_	_
22-21	2710-2719	PD-L1/PD1	abstract[145]|abstract[146]|abstract[148]|object|abstract[150]	new[145]|new[146]|new[148]|new|giv[150]	_	_
22-22	2720-2724	axis	abstract[145]|abstract[146]|abstract[148]|abstract[150]	new[145]|new[146]|new[148]|giv[150]	_	_
22-23	2725-2726	.	_	_	_	_

#Text=A thorough understanding of the nature of this relationship requires further work .
23-1	2727-2728	A	abstract[151]	new[151]	_	_
23-2	2729-2737	thorough	abstract[151]	new[151]	_	_
23-3	2738-2751	understanding	abstract[151]	new[151]	_	_
23-4	2752-2754	of	abstract[151]	new[151]	_	_
23-5	2755-2758	the	abstract[151]|abstract[152]	new[151]|new[152]	_	_
23-6	2759-2765	nature	abstract[151]|abstract[152]	new[151]|new[152]	_	_
23-7	2766-2768	of	abstract[151]|abstract[152]	new[151]|new[152]	_	_
23-8	2769-2773	this	abstract[151]|abstract[152]|abstract[153]	new[151]|new[152]|giv[153]	_	_
23-9	2774-2786	relationship	abstract[151]|abstract[152]|abstract[153]	new[151]|new[152]|giv[153]	_	_
23-10	2787-2795	requires	_	_	_	_
23-11	2796-2803	further	abstract[154]	new[154]	ana	25-1[0_154]
23-12	2804-2808	work	abstract[154]	new[154]	_	_
23-13	2809-2810	.	_	_	_	_

#Text=EGF is another molecule with similar effects .
24-1	2811-2814	EGF	substance	new	coref	24-3[156_0]
24-2	2815-2817	is	_	_	_	_
24-3	2818-2825	another	substance[156]	giv[156]	coref	37-7[243_156]
24-4	2826-2834	molecule	substance[156]	giv[156]	_	_
24-5	2835-2839	with	substance[156]	giv[156]	_	_
24-6	2840-2847	similar	substance[156]|abstract[157]	giv[156]|new[157]	_	_
24-7	2848-2855	effects	substance[156]|abstract[157]	giv[156]|new[157]	_	_
24-8	2856-2857	.	_	_	_	_

#Text=It promotes tumor angiogenesis as well as an increase in cell motility and invasiveness .
25-1	2858-2860	It	abstract	giv	_	_
25-2	2861-2869	promotes	_	_	_	_
25-3	2870-2875	tumor	object|abstract[160]	giv|giv[160]	coref|coref	27-15[175_160]|28-6
25-4	2876-2888	angiogenesis	abstract[160]	giv[160]	_	_
25-5	2889-2891	as	_	_	_	_
25-6	2892-2896	well	_	_	_	_
25-7	2897-2899	as	_	_	_	_
25-8	2900-2902	an	event[161]	new[161]	ana	26-1[0_161]
25-9	2903-2911	increase	event[161]	new[161]	_	_
25-10	2912-2914	in	event[161]	new[161]	_	_
25-11	2915-2919	cell	event[161]|place|abstract[163]	new[161]|giv|new[163]	coref	30-13[202_0]
25-12	2920-2928	motility	event[161]|abstract[163]	new[161]|new[163]	_	_
25-13	2929-2932	and	event[161]	new[161]	_	_
25-14	2933-2945	invasiveness	event[161]|abstract	new[161]|giv	coref	36-14[240_0]
25-15	2946-2947	.	_	_	_	_

#Text=This is done by phosphorylating the EGFR receptor and activating further signaling pathways .
26-1	2948-2952	This	event	giv	coref	29-11[187_0]
26-2	2953-2955	is	_	_	_	_
26-3	2956-2960	done	_	_	_	_
26-4	2961-2963	by	_	_	_	_
26-5	2964-2979	phosphorylating	_	_	_	_
26-6	2980-2983	the	abstract[167]	new[167]	ana	27-1[0_167]
26-7	2984-2988	EGFR	abstract|abstract[167]	new|new[167]	coref	27-6[170_0]
26-8	2989-2997	receptor	abstract[167]	new[167]	_	_
26-9	2998-3001	and	_	_	_	_
26-10	3002-3012	activating	_	_	_	_
26-11	3013-3020	further	abstract[168]	giv[168]	_	_
26-12	3021-3030	signaling	abstract[168]	giv[168]	_	_
26-13	3031-3039	pathways	abstract[168]	giv[168]	_	_
26-14	3040-3041	.	_	_	_	_

#Text=It has been shown that both EGFR and its mutated form of EGFRvIII promote GBM angiogenesis .
27-1	3042-3044	It	abstract	giv	ana	27-9
27-2	3045-3048	has	_	_	_	_
27-3	3049-3053	been	_	_	_	_
27-4	3054-3059	shown	_	_	_	_
27-5	3060-3064	that	_	_	_	_
27-6	3065-3069	both	abstract[170]	giv[170]	coref	29-9[0_170]
27-7	3070-3074	EGFR	abstract[170]	giv[170]	_	_
27-8	3075-3078	and	_	_	_	_
27-9	3079-3082	its	abstract|substance[172]	giv|new[172]	coref	35-25[232_0]
27-10	3083-3090	mutated	substance[172]	new[172]	_	_
27-11	3091-3095	form	substance[172]	new[172]	_	_
27-12	3096-3098	of	substance[172]	new[172]	_	_
27-13	3099-3107	EGFRvIII	substance[172]|abstract	new[172]|new	_	_
27-14	3108-3115	promote	_	_	_	_
27-15	3116-3119	GBM	abstract|abstract[175]	giv|giv[175]	coref	30-26[0_175]
27-16	3120-3132	angiogenesis	abstract[175]	giv[175]	_	_
27-17	3133-3134	.	_	_	_	_

#Text=To allow vasculature growth and tumor invasion , it is necessary to reduce the integrity of the tumor microenvironment .
28-1	3135-3137	To	_	_	_	_
28-2	3138-3143	allow	_	_	_	_
28-3	3144-3155	vasculature	organization|abstract[177]	new|giv[177]	coref	40-17[0_177]
28-4	3156-3162	growth	abstract[177]	giv[177]	_	_
28-5	3163-3166	and	_	_	_	_
28-6	3167-3172	tumor	object|event[179]	giv|new[179]	ana|coref	28-9[0_179]|28-18
28-7	3173-3181	invasion	event[179]	new[179]	_	_
28-8	3182-3183	,	_	_	_	_
28-9	3184-3186	it	event	giv	coref	30-13[203_0]
28-10	3187-3189	is	_	_	_	_
28-11	3190-3199	necessary	_	_	_	_
28-12	3200-3202	to	_	_	_	_
28-13	3203-3209	reduce	_	_	_	_
28-14	3210-3213	the	abstract[181]	new[181]	coref	30-7[199_181]
28-15	3214-3223	integrity	abstract[181]	new[181]	_	_
28-16	3224-3226	of	abstract[181]	new[181]	_	_
28-17	3227-3230	the	abstract[181]|abstract[183]	new[181]|giv[183]	coref	30-7[0_183]
28-18	3231-3236	tumor	abstract[181]|object|abstract[183]	new[181]|giv|giv[183]	coref	30-13
28-19	3237-3253	microenvironment	abstract[181]|abstract[183]	new[181]|giv[183]	_	_
28-20	3254-3255	.	_	_	_	_

#Text=The pathophysiology of this process is based on EGFR inducing an increase in the activity of some proteases , thereby causing the breakdown of collagen , fibronectin , and other basement membrane structures .
29-1	3256-3259	The	abstract[184]	new[184]	_	_
29-2	3260-3275	pathophysiology	abstract[184]	new[184]	_	_
29-3	3276-3278	of	abstract[184]	new[184]	_	_
29-4	3279-3283	this	abstract[184]|abstract[185]	new[184]|new[185]	_	_
29-5	3284-3291	process	abstract[184]|abstract[185]	new[184]|new[185]	_	_
29-6	3292-3294	is	_	_	_	_
29-7	3295-3300	based	_	_	_	_
29-8	3301-3303	on	_	_	_	_
29-9	3304-3308	EGFR	abstract	giv	coref	31-8
29-10	3309-3317	inducing	_	_	_	_
29-11	3318-3320	an	event[187]	giv[187]	coref	30-10[200_187]
29-12	3321-3329	increase	event[187]	giv[187]	_	_
29-13	3330-3332	in	event[187]	giv[187]	_	_
29-14	3333-3336	the	event[187]|abstract[188]	giv[187]|new[188]	coref	31-3[210_188]
29-15	3337-3345	activity	event[187]|abstract[188]	giv[187]|new[188]	_	_
29-16	3346-3348	of	event[187]|abstract[188]	giv[187]|new[188]	_	_
29-17	3349-3353	some	event[187]|abstract[188]|animal[189]	giv[187]|new[188]|new[189]	coref	31-1[209_189]
29-18	3354-3363	proteases	event[187]|abstract[188]|animal[189]	giv[187]|new[188]|new[189]	_	_
29-19	3364-3365	,	_	_	_	_
29-20	3366-3373	thereby	_	_	_	_
29-21	3374-3381	causing	_	_	_	_
29-22	3382-3385	the	event[190]	new[190]	_	_
29-23	3386-3395	breakdown	event[190]	new[190]	_	_
29-24	3396-3398	of	event[190]	new[190]	_	_
29-25	3399-3407	collagen	event[190]|substance	new[190]|new	_	_
29-26	3408-3409	,	event[190]	new[190]	_	_
29-27	3410-3421	fibronectin	event[190]|object	new[190]|new	_	_
29-28	3422-3423	,	event[190]	new[190]	_	_
29-29	3424-3427	and	event[190]	new[190]	_	_
29-30	3428-3433	other	event[190]|abstract[194]	new[190]|new[194]	_	_
29-31	3434-3442	basement	event[190]|object[193]|abstract[194]	new[190]|new[193]|new[194]	_	_
29-32	3443-3451	membrane	event[190]|object[193]|abstract[194]	new[190]|new[193]|new[194]	_	_
29-33	3452-3462	structures	event[190]|abstract[194]	new[190]|new[194]	_	_
29-34	3463-3464	.	_	_	_	_

#Text=The result is a loss of microenvironment integrity , an increase in tumor cell invasion into surrounding tissues and vessels , and an increase in angiogenesis .
30-1	3465-3468	The	event[195]	new[195]	coref	30-4[196_195]
30-2	3469-3475	result	event[195]	new[195]	_	_
30-3	3476-3478	is	_	_	_	_
30-4	3479-3480	a	event[196]|event[197]	giv[196]|giv[197]	coref	30-4[197_196]
30-5	3481-3485	loss	event[196]|event[197]	giv[196]|giv[197]	_	_
30-6	3486-3488	of	event[196]|event[197]	giv[196]|giv[197]	_	_
30-7	3489-3505	microenvironment	event[196]|event[197]|abstract|abstract[199]	giv[196]|giv[197]|giv|giv[199]	coref|coref	44-10[296_199]|48-15[329_0]
30-8	3506-3515	integrity	event[196]|event[197]|abstract[199]	giv[196]|giv[197]|giv[199]	_	_
30-9	3516-3517	,	event[197]	giv[197]	_	_
30-10	3518-3520	an	event[197]|event[200]	giv[197]|giv[200]	coref	30-23[207_200]
30-11	3521-3529	increase	event[197]|event[200]	giv[197]|giv[200]	_	_
30-12	3530-3532	in	event[197]|event[200]	giv[197]|giv[200]	_	_
30-13	3533-3538	tumor	event[197]|event[200]|object|place[202]|event[203]	giv[197]|giv[200]|giv|giv[202]|giv[203]	coref|coref|coref	39-10|43-18[0_202]|46-7[315_203]
30-14	3539-3543	cell	event[197]|event[200]|place[202]|event[203]	giv[197]|giv[200]|giv[202]|giv[203]	_	_
30-15	3544-3552	invasion	event[197]|event[200]|event[203]	giv[197]|giv[200]|giv[203]	_	_
30-16	3553-3557	into	event[197]|event[200]|event[203]	giv[197]|giv[200]|giv[203]	_	_
30-17	3558-3569	surrounding	event[197]|event[200]|event[203]|object[204]|abstract[205]	giv[197]|giv[200]|giv[203]|new[204]|giv[205]	_	_
30-18	3570-3577	tissues	event[197]|event[200]|event[203]|object[204]|abstract[205]	giv[197]|giv[200]|giv[203]|new[204]|giv[205]	_	_
30-19	3578-3581	and	event[197]|event[200]|event[203]|abstract[205]	giv[197]|giv[200]|giv[203]|giv[205]	_	_
30-20	3582-3589	vessels	event[197]|event[200]|event[203]|abstract[205]|object	giv[197]|giv[200]|giv[203]|giv[205]|new	_	_
30-21	3590-3591	,	event[197]	giv[197]	_	_
30-22	3592-3595	and	event[197]	giv[197]	_	_
30-23	3596-3598	an	event[197]|event[207]	giv[197]|giv[207]	coref	38-6[251_207]
30-24	3599-3607	increase	event[197]|event[207]	giv[197]|giv[207]	_	_
30-25	3608-3610	in	event[197]|event[207]	giv[197]|giv[207]	_	_
30-26	3611-3623	angiogenesis	event[197]|event[207]|abstract	giv[197]|giv[207]|giv	_	_
30-27	3624-3625	.	_	_	_	_

#Text=The proteases whose activity is influenced by EGFR include , among others :
31-1	3626-3629	The	animal[209]	giv[209]	coref	35-8[222_209]
31-2	3630-3639	proteases	animal[209]	giv[209]	_	_
31-3	3640-3645	whose	animal[209]|abstract[210]	giv[209]|giv[210]	coref	39-4[256_210]
31-4	3646-3654	activity	animal[209]|abstract[210]	giv[209]|giv[210]	_	_
31-5	3655-3657	is	animal[209]	giv[209]	_	_
31-6	3658-3668	influenced	animal[209]	giv[209]	_	_
31-7	3669-3671	by	animal[209]	giv[209]	_	_
31-8	3672-3676	EGFR	animal[209]|abstract	giv[209]|giv	coref	40-14
31-9	3677-3684	include	_	_	_	_
31-10	3685-3686	,	_	_	_	_
31-11	3687-3692	among	_	_	_	_
31-12	3693-3699	others	_	_	_	_
31-13	3700-3701	:	_	_	_	_

#Text=Serine Proteases
32-1	3702-3708	Serine	substance|person[213]	new|new[213]	coref|coref	35-1|35-1[220_213]
32-2	3709-3718	Proteases	person[213]	new[213]	_	_

#Text=Matrix Metalloproteases ( MMPs )
33-1	3719-3725	Matrix	abstract|substance[215]	new|new[215]	coref|coref	45-10|45-9[300_215]
33-2	3726-3742	Metalloproteases	substance[215]	new[215]	_	_
33-3	3743-3744	(	_	_	_	_
33-4	3745-3749	MMPs	abstract	new	_	_
33-5	3750-3751	)	_	_	_	_

#Text=Cysteine Proteases .
34-1	3752-3760	Cysteine	abstract|event[218]	new|new[218]	coref	47-6
34-2	3761-3770	Proteases	event[218]	new[218]	_	_
34-3	3771-3772	.	_	_	_	_

#Text=Serine proteases are a large group of proteases which include tissue plasminogen activator ( tPA ) and urokinase plasminogen activator ( uPA ) with its receptor ( uPAR ) .
35-1	3773-3779	Serine	substance|person[220]	giv|giv[220]	coref	35-4[221_220]
35-2	3780-3789	proteases	person[220]	giv[220]	_	_
35-3	3790-3793	are	_	_	_	_
35-4	3794-3795	a	person[221]	giv[221]	ana	36-1[0_221]
35-5	3796-3801	large	person[221]	giv[221]	_	_
35-6	3802-3807	group	person[221]	giv[221]	_	_
35-7	3808-3810	of	person[221]	giv[221]	_	_
35-8	3811-3820	proteases	person[221]|animal[222]	giv[221]|giv[222]	coref	42-11[0_222]
35-9	3821-3826	which	person[221]|animal[222]	giv[221]|giv[222]	_	_
35-10	3827-3834	include	person[221]|animal[222]	giv[221]|giv[222]	_	_
35-11	3835-3841	tissue	person[221]|animal[222]|object|abstract[225]	giv[221]|giv[222]|new|new[225]	appos	35-15[0_225]
35-12	3842-3853	plasminogen	person[221]|animal[222]|substance|abstract[225]	giv[221]|giv[222]|new|new[225]	coref	35-19
35-13	3854-3863	activator	person[221]|animal[222]|abstract[225]	giv[221]|giv[222]|new[225]	_	_
35-14	3864-3865	(	_	_	_	_
35-15	3866-3869	tPA	abstract	giv	_	_
35-16	3870-3871	)	_	_	_	_
35-17	3872-3875	and	_	_	_	_
35-18	3876-3885	urokinase	animal|abstract[229]	new|new[229]	appos	35-22[0_229]
35-19	3886-3897	plasminogen	substance|abstract[229]	giv|new[229]	_	_
35-20	3898-3907	activator	abstract[229]	new[229]	_	_
35-21	3908-3909	(	_	_	_	_
35-22	3910-3913	uPA	abstract	giv	ana	35-25
35-23	3914-3915	)	_	_	_	_
35-24	3916-3920	with	_	_	_	_
35-25	3921-3924	its	abstract|abstract[232]	giv|giv[232]	appos|coref	35-28[0_232]|40-3
35-26	3925-3933	receptor	abstract[232]	giv[232]	_	_
35-27	3934-3935	(	_	_	_	_
35-28	3936-3940	uPAR	abstract	giv	coref	40-5
35-29	3941-3942	)	_	_	_	_
35-30	3943-3944	.	_	_	_	_

#Text=Their activation affects the degradation of the extracellular space by tumors , promoting their invasiveness .
36-1	3945-3950	Their	person|event[235]	giv|new[235]	ana	36-14
36-2	3951-3961	activation	event[235]	new[235]	_	_
36-3	3962-3969	affects	_	_	_	_
36-4	3970-3973	the	event[236]	new[236]	_	_
36-5	3974-3985	degradation	event[236]	new[236]	_	_
36-6	3986-3988	of	event[236]	new[236]	_	_
36-7	3989-3992	the	event[236]|place[237]	new[236]|new[237]	_	_
36-8	3993-4006	extracellular	event[236]|place[237]	new[236]|new[237]	_	_
36-9	4007-4012	space	event[236]|place[237]	new[236]|new[237]	_	_
36-10	4013-4015	by	event[236]	new[236]	_	_
36-11	4016-4022	tumors	event[236]|animal	new[236]|new	_	_
36-12	4023-4024	,	_	_	_	_
36-13	4025-4034	promoting	_	_	_	_
36-14	4035-4040	their	person|abstract[240]	giv|giv[240]	ana	37-1[0_240]
36-15	4041-4053	invasiveness	abstract[240]	giv[240]	_	_
36-16	4054-4055	.	_	_	_	_

#Text=It has been shown that , the PAI-1 molecule mediates the regulation of the uPA/uPAR pathway in astrocytoma cells .
37-1	4056-4058	It	abstract	giv	coref	39-10[258_0]
37-2	4059-4062	has	_	_	_	_
37-3	4063-4067	been	_	_	_	_
37-4	4068-4073	shown	_	_	_	_
37-5	4074-4078	that	_	_	_	_
37-6	4079-4080	,	_	_	_	_
37-7	4081-4084	the	substance[243]	giv[243]	coref	38-9[0_243]
37-8	4085-4090	PAI-1	substance|substance[243]	new|giv[243]	coref	41-8[270_0]
37-9	4091-4099	molecule	substance[243]	giv[243]	_	_
37-10	4100-4108	mediates	_	_	_	_
37-11	4109-4112	the	abstract[244]	new[244]	_	_
37-12	4113-4123	regulation	abstract[244]	new[244]	_	_
37-13	4124-4126	of	abstract[244]	new[244]	_	_
37-14	4127-4130	the	abstract[244]|abstract[246]	new[244]|new[246]	ana	38-1[0_246]
37-15	4131-4139	uPA/uPAR	abstract[244]|abstract|abstract[246]	new[244]|new|new[246]	coref	39-5
37-16	4140-4147	pathway	abstract[244]|abstract[246]	new[244]|new[246]	_	_
37-17	4148-4150	in	_	_	_	_
37-18	4151-4162	astrocytoma	abstract|animal[248]	new|new[248]	_	_
37-19	4163-4168	cells	animal[248]	new[248]	_	_
37-20	4169-4170	.	_	_	_	_

#Text=Its expression is promoted by an increase in EGF and inflammatory cytokines .
38-1	4171-4174	Its	abstract|abstract[250]	giv|giv[250]	coref	40-10[262_250]
38-2	4175-4185	expression	abstract[250]	giv[250]	_	_
38-3	4186-4188	is	_	_	_	_
38-4	4189-4197	promoted	_	_	_	_
38-5	4198-4200	by	_	_	_	_
38-6	4201-4203	an	event[251]	giv[251]	ana	39-1[0_251]
38-7	4204-4212	increase	event[251]	giv[251]	_	_
38-8	4213-4215	in	event[251]	giv[251]	_	_
38-9	4216-4219	EGF	event[251]|substance	giv[251]|giv	coref	42-1
38-10	4220-4223	and	event[251]	giv[251]	_	_
38-11	4224-4236	inflammatory	event[251]|abstract[253]	giv[251]|new[253]	_	_
38-12	4237-4246	cytokines	event[251]|abstract[253]	giv[251]|new[253]	_	_
38-13	4247-4248	.	_	_	_	_

#Text=This results in greater uPA/uPAR activity , thus increasing tumor invasiveness .
39-1	4249-4253	This	event	giv	_	_
39-2	4254-4261	results	_	_	_	_
39-3	4262-4264	in	_	_	_	_
39-4	4265-4272	greater	abstract[256]	giv[256]	coref	41-12[0_256]
39-5	4273-4281	uPA/uPAR	abstract|abstract[256]	giv|giv[256]	_	_
39-6	4282-4290	activity	abstract[256]	giv[256]	_	_
39-7	4291-4292	,	_	_	_	_
39-8	4293-4297	thus	_	_	_	_
39-9	4298-4308	increasing	_	_	_	_
39-10	4309-4314	tumor	object|abstract[258]	giv|giv[258]	coref	41-16
39-11	4315-4327	invasiveness	abstract[258]	giv[258]	_	_
39-12	4328-4329	.	_	_	_	_

#Text=Upregulation of uPA and uPAR is also achieved through the expression of the EGFR ligand transforming growth factor ( TGFα ) .
40-1	4330-4342	Upregulation	abstract[259]	new[259]	_	_
40-2	4343-4345	of	abstract[259]	new[259]	_	_
40-3	4346-4349	uPA	abstract[259]|abstract	new[259]|giv	coref	52-21
40-4	4350-4353	and	abstract[259]	new[259]	_	_
40-5	4354-4358	uPAR	abstract[259]|abstract	new[259]|giv	_	_
40-6	4359-4361	is	_	_	_	_
40-7	4362-4366	also	_	_	_	_
40-8	4367-4375	achieved	_	_	_	_
40-9	4376-4383	through	_	_	_	_
40-10	4384-4387	the	abstract[262]	giv[262]	coref	49-1[331_262]
40-11	4388-4398	expression	abstract[262]	giv[262]	_	_
40-12	4399-4401	of	abstract[262]	giv[262]	_	_
40-13	4402-4405	the	abstract[262]|abstract[264]	giv[262]|new[264]	appos	40-16[266_264]
40-14	4406-4410	EGFR	abstract[262]|abstract|abstract[264]	giv[262]|giv|new[264]	coref	41-11
40-15	4411-4417	ligand	abstract[262]|abstract[264]	giv[262]|new[264]	_	_
40-16	4418-4430	transforming	abstract[266]	giv[266]	appos	40-20[0_266]
40-17	4431-4437	growth	abstract|abstract[266]	giv|giv[266]	_	_
40-18	4438-4444	factor	abstract[266]	giv[266]	_	_
40-19	4445-4446	(	_	_	_	_
40-20	4447-4451	TGFα	abstract	giv	_	_
40-21	4452-4453	)	_	_	_	_
40-22	4454-4455	.	_	_	_	_

#Text=Studies confirmed that in malignant gliomas , both PAI-1 and EGFR activity correlate with higher tumor malignancy and worse prognosis for patients .
41-1	4456-4463	Studies	abstract	giv	_	_
41-2	4464-4473	confirmed	_	_	_	_
41-3	4474-4478	that	_	_	_	_
41-4	4479-4481	in	_	_	_	_
41-5	4482-4491	malignant	abstract[269]	new[269]	coref	45-39[311_269]
41-6	4492-4499	gliomas	abstract[269]	new[269]	_	_
41-7	4500-4501	,	_	_	_	_
41-8	4502-4506	both	substance[270]	giv[270]	_	_
41-9	4507-4512	PAI-1	substance[270]	giv[270]	_	_
41-10	4513-4516	and	_	_	_	_
41-11	4517-4521	EGFR	abstract	giv	coref	49-13
41-12	4522-4530	activity	abstract	giv	_	_
41-13	4531-4540	correlate	_	_	_	_
41-14	4541-4545	with	_	_	_	_
41-15	4546-4552	higher	abstract[274]	new[274]	coref	46-13[0_274]
41-16	4553-4558	tumor	object|abstract[274]	giv|new[274]	coref	46-7
41-17	4559-4569	malignancy	abstract[274]	new[274]	_	_
41-18	4570-4573	and	_	_	_	_
41-19	4574-4579	worse	abstract[275]	new[275]	_	_
41-20	4580-4589	prognosis	abstract[275]	new[275]	_	_
41-21	4590-4593	for	abstract[275]	new[275]	_	_
41-22	4594-4602	patients	abstract[275]|person	new[275]|new	_	_
41-23	4603-4604	.	_	_	_	_

#Text=EGF also has a potential impact on another group of proteases , i.e. , MMPs .
42-1	4605-4608	EGF	substance	giv	_	_
42-2	4609-4613	also	_	_	_	_
42-3	4614-4617	has	_	_	_	_
42-4	4618-4619	a	abstract[278]	new[278]	_	_
42-5	4620-4629	potential	abstract[278]	new[278]	_	_
42-6	4630-4636	impact	abstract[278]	new[278]	_	_
42-7	4637-4639	on	abstract[278]	new[278]	_	_
42-8	4640-4647	another	abstract[278]|abstract[279]	new[278]|new[279]	coref	47-1[319_279]
42-9	4648-4653	group	abstract[278]|abstract[279]	new[278]|new[279]	_	_
42-10	4654-4656	of	abstract[278]|abstract[279]	new[278]|new[279]	_	_
42-11	4657-4666	proteases	abstract[278]|abstract[279]|animal	new[278]|new[279]|giv	coref	47-4
42-12	4667-4668	,	_	_	_	_
42-13	4669-4673	i.e.	abstract[281]	new[281]	ana	43-1[0_281]
42-14	4674-4675	,	abstract[281]	new[281]	_	_
42-15	4676-4680	MMPs	abstract[281]	new[281]	_	_
42-16	4681-4682	.	_	_	_	_

#Text=They are a large group of enzymes whose effect is based on the regulation of metabolism and cell morphogenesis .
43-1	4683-4687	They	abstract	giv	coref	43-3[283_0]
43-2	4688-4691	are	_	_	_	_
43-3	4692-4693	a	abstract[283]	giv[283]	coref	52-23[0_283]
43-4	4694-4699	large	abstract[283]	giv[283]	_	_
43-5	4700-4705	group	abstract[283]	giv[283]	_	_
43-6	4706-4708	of	abstract[283]	giv[283]	_	_
43-7	4709-4716	enzymes	abstract[283]|substance[284]	giv[283]|new[284]	_	_
43-8	4717-4722	whose	abstract[283]|substance[284]|abstract[285]	giv[283]|new[284]|new[285]	_	_
43-9	4723-4729	effect	abstract[283]|substance[284]|abstract[285]	giv[283]|new[284]|new[285]	_	_
43-10	4730-4732	is	abstract[283]|substance[284]	giv[283]|new[284]	_	_
43-11	4733-4738	based	abstract[283]|substance[284]	giv[283]|new[284]	_	_
43-12	4739-4741	on	abstract[283]|substance[284]	giv[283]|new[284]	_	_
43-13	4742-4745	the	abstract[283]|substance[284]|abstract[286]	giv[283]|new[284]|new[286]	_	_
43-14	4746-4756	regulation	abstract[283]|substance[284]|abstract[286]	giv[283]|new[284]|new[286]	_	_
43-15	4757-4759	of	abstract[283]|substance[284]|abstract[286]	giv[283]|new[284]|new[286]	_	_
43-16	4760-4770	metabolism	abstract[283]|substance[284]|abstract[286]|abstract|abstract[288]	giv[283]|new[284]|new[286]|new|new[288]	ana	44-3[0_288]
43-17	4771-4774	and	abstract[283]|substance[284]|abstract[286]|abstract[288]	giv[283]|new[284]|new[286]|new[288]	_	_
43-18	4775-4779	cell	abstract[283]|substance[284]|abstract[286]|abstract[288]|place|abstract[290]	giv[283]|new[284]|new[286]|new[288]|giv|new[290]	coref	44-10
43-19	4780-4793	morphogenesis	abstract[283]|substance[284]|abstract[286]|abstract[288]|abstract[290]	giv[283]|new[284]|new[286]|new[288]|new[290]	_	_
43-20	4794-4795	.	_	_	_	_

#Text=Disruption of their function also affects the loss of cell integrity .
44-1	4796-4806	Disruption	abstract[291]	new[291]	_	_
44-2	4807-4809	of	abstract[291]	new[291]	_	_
44-3	4810-4815	their	abstract[291]|abstract|abstract[293]	new[291]|giv|new[293]	_	_
44-4	4816-4824	function	abstract[291]|abstract[293]	new[291]|new[293]	_	_
44-5	4825-4829	also	_	_	_	_
44-6	4830-4837	affects	_	_	_	_
44-7	4838-4841	the	event[294]	new[294]	_	_
44-8	4842-4846	loss	event[294]	new[294]	_	_
44-9	4847-4849	of	event[294]	new[294]	_	_
44-10	4850-4854	cell	event[294]|place|abstract[296]	new[294]|giv|giv[296]	ana	45-1[0_296]
44-11	4855-4864	integrity	event[294]|abstract[296]	new[294]|giv[296]	_	_
44-12	4865-4866	.	_	_	_	_

#Text=It has been shown that the activity of certain matrix metalloproteases , such as MMP-2 ( gelatinase A ) , MMP-9 ( gelatinase B ) , MMP-14 ( matrix metalloproteinase 14 ) is related to the pathophysiology of high-grade gliomas .
45-1	4867-4869	It	abstract	giv	_	_
45-2	4870-4873	has	_	_	_	_
45-3	4874-4878	been	_	_	_	_
45-4	4879-4884	shown	_	_	_	_
45-5	4885-4889	that	_	_	_	_
45-6	4890-4893	the	abstract[298]	new[298]	_	_
45-7	4894-4902	activity	abstract[298]	new[298]	_	_
45-8	4903-4905	of	abstract[298]	new[298]	_	_
45-9	4906-4913	certain	abstract[298]|substance[300]	new[298]|giv[300]	_	_
45-10	4914-4920	matrix	abstract[298]|abstract|substance[300]	new[298]|giv|giv[300]	coref	45-29
45-11	4921-4937	metalloproteases	abstract[298]|substance[300]	new[298]|giv[300]	_	_
45-12	4938-4939	,	abstract[298]|substance[300]	new[298]|giv[300]	_	_
45-13	4940-4944	such	abstract[298]|substance[300]	new[298]|giv[300]	_	_
45-14	4945-4947	as	abstract[298]|substance[300]	new[298]|giv[300]	_	_
45-15	4948-4953	MMP-2	abstract[298]|substance[300]|abstract	new[298]|giv[300]|new	appos	45-17[302_0]
45-16	4954-4955	(	_	_	_	_
45-17	4956-4966	gelatinase	abstract[302]	giv[302]	appos	45-23[0_302]
45-18	4967-4968	A	abstract[302]	giv[302]	_	_
45-19	4969-4970	)	_	_	_	_
45-20	4971-4972	,	_	_	_	_
45-21	4973-4978	MMP-9	abstract	new	_	_
45-22	4979-4980	(	_	_	_	_
45-23	4981-4991	gelatinase	abstract	giv	_	_
45-24	4992-4993	B	place	new	_	_
45-25	4994-4995	)	_	_	_	_
45-26	4996-4997	,	_	_	_	_
45-27	4998-5004	MMP-14	abstract	new	_	_
45-28	5005-5006	(	_	_	_	_
45-29	5007-5013	matrix	abstract|substance[308]	giv|new[308]	appos	45-31[0_308]
45-30	5014-5031	metalloproteinase	substance[308]	new[308]	_	_
45-31	5032-5034	14	substance	giv	_	_
45-32	5035-5036	)	_	_	_	_
45-33	5037-5039	is	_	_	_	_
45-34	5040-5047	related	_	_	_	_
45-35	5048-5050	to	_	_	_	_
45-36	5051-5054	the	abstract[310]	new[310]	ana	46-1[0_310]
45-37	5055-5070	pathophysiology	abstract[310]	new[310]	_	_
45-38	5071-5073	of	abstract[310]	new[310]	_	_
45-39	5074-5084	high-grade	abstract[310]|abstract[311]	new[310]|giv[311]	coref	50-11[0_311]
45-40	5085-5092	gliomas	abstract[310]|abstract[311]	new[310]|giv[311]	_	_
45-41	5093-5094	.	_	_	_	_

#Text=It correlates with the severity of tumor invasion and its degree of malignancy .
46-1	5095-5097	It	abstract	giv	ana	46-10
46-2	5098-5108	correlates	_	_	_	_
46-3	5109-5113	with	_	_	_	_
46-4	5114-5117	the	abstract[313]	new[313]	_	_
46-5	5118-5126	severity	abstract[313]	new[313]	_	_
46-6	5127-5129	of	abstract[313]	new[313]	_	_
46-7	5130-5135	tumor	abstract[313]|object|event[315]	new[313]|giv|giv[315]	coref	48-16
46-8	5136-5144	invasion	abstract[313]|event[315]	new[313]|giv[315]	_	_
46-9	5145-5148	and	_	_	_	_
46-10	5149-5152	its	abstract|abstract[317]	giv|new[317]	_	_
46-11	5153-5159	degree	abstract[317]	new[317]	_	_
46-12	5160-5162	of	abstract[317]	new[317]	_	_
46-13	5163-5173	malignancy	abstract[317]|abstract	new[317]|giv	_	_
46-14	5174-5175	.	_	_	_	_

#Text=Another group of proteases are cysteine proteases , examples of which are cathepsins .
47-1	5176-5183	Another	abstract[319]	giv[319]	coref	47-6[322_319]
47-2	5184-5189	group	abstract[319]	giv[319]	_	_
47-3	5190-5192	of	abstract[319]	giv[319]	_	_
47-4	5193-5202	proteases	abstract[319]|animal	giv[319]|giv	_	_
47-5	5203-5206	are	_	_	_	_
47-6	5207-5215	cysteine	abstract|abstract[322]	giv|giv[322]	ana	48-1[0_322]
47-7	5216-5225	proteases	abstract[322]	giv[322]	_	_
47-8	5226-5227	,	abstract[322]	giv[322]	_	_
47-9	5228-5236	examples	abstract[322]|abstract[323]|person[324]	giv[322]|new[323]|new[324]	_	_
47-10	5237-5239	of	abstract[322]|abstract[323]|person[324]	giv[322]|new[323]|new[324]	_	_
47-11	5240-5245	which	abstract[322]|abstract[323]|person[324]	giv[322]|new[323]|new[324]	_	_
47-12	5246-5249	are	abstract[322]|person[324]	giv[322]|new[324]	_	_
47-13	5250-5260	cathepsins	abstract[322]|person[324]	giv[322]|new[324]	_	_
47-14	5261-5262	.	_	_	_	_

#Text=These include , among others , cathepsin B , involved in the degradation of the tumor microenvironment .
48-1	5263-5268	These	abstract	giv	_	_
48-2	5269-5276	include	_	_	_	_
48-3	5277-5278	,	_	_	_	_
48-4	5279-5284	among	_	_	_	_
48-5	5285-5291	others	_	_	_	_
48-6	5292-5293	,	_	_	_	_
48-7	5294-5303	cathepsin	person[326]	new[326]	coref	51-4[342_326]
48-8	5304-5305	B	person[326]	new[326]	_	_
48-9	5306-5307	,	person[326]	new[326]	_	_
48-10	5308-5316	involved	person[326]	new[326]	_	_
48-11	5317-5319	in	person[326]	new[326]	_	_
48-12	5320-5323	the	person[326]|abstract[327]	new[326]|new[327]	_	_
48-13	5324-5335	degradation	person[326]|abstract[327]	new[326]|new[327]	_	_
48-14	5336-5338	of	person[326]|abstract[327]	new[326]|new[327]	_	_
48-15	5339-5342	the	person[326]|abstract[327]|abstract[329]	new[326]|new[327]|giv[329]	ana	49-1[0_329]
48-16	5343-5348	tumor	person[326]|abstract[327]|object|abstract[329]	new[326]|new[327]|giv|giv[329]	coref	52-12[347_0]
48-17	5349-5365	microenvironment	person[326]|abstract[327]|abstract[329]	new[326]|new[327]|giv[329]	_	_
48-18	5366-5367	.	_	_	_	_

#Text=Its expression ( mRNA level ) has been shown to correlate with EGFR expression level .
49-1	5368-5371	Its	abstract|abstract[331]	giv|giv[331]	appos	49-4[333_331]
49-2	5372-5382	expression	abstract[331]	giv[331]	_	_
49-3	5383-5384	(	_	_	_	_
49-4	5385-5389	mRNA	abstract|abstract[333]	new|giv[333]	coref	49-14[0_333]
49-5	5390-5395	level	abstract[333]	giv[333]	_	_
49-6	5396-5397	)	_	_	_	_
49-7	5398-5401	has	_	_	_	_
49-8	5402-5406	been	_	_	_	_
49-9	5407-5412	shown	_	_	_	_
49-10	5413-5415	to	_	_	_	_
49-11	5416-5425	correlate	_	_	_	_
49-12	5426-5430	with	_	_	_	_
49-13	5431-5435	EGFR	abstract|abstract[336]	giv|giv[336]	coref|ana	49-13[336_0]|50-1[0_336]
49-14	5436-5446	expression	abstract|abstract[336]	giv|giv[336]	_	_
49-15	5447-5452	level	abstract[336]	giv[336]	_	_
49-16	5453-5454	.	_	_	_	_

#Text=It was also confirmed that its presence is increased in gliomas .
50-1	5455-5457	It	abstract	giv	ana	50-6
50-2	5458-5461	was	_	_	_	_
50-3	5462-5466	also	_	_	_	_
50-4	5467-5476	confirmed	_	_	_	_
50-5	5477-5481	that	_	_	_	_
50-6	5482-5485	its	abstract|abstract[339]	giv|new[339]	ana	52-1[0_339]
50-7	5486-5494	presence	abstract[339]	new[339]	_	_
50-8	5495-5497	is	_	_	_	_
50-9	5498-5507	increased	_	_	_	_
50-10	5508-5510	in	_	_	_	_
50-11	5511-5518	gliomas	abstract	giv	_	_
50-12	5519-5520	.	_	_	_	_

#Text=The action of cathepsin B may be bidirectional .
51-1	5521-5524	The	event[341]	new[341]	_	_
51-2	5525-5531	action	event[341]	new[341]	_	_
51-3	5532-5534	of	event[341]	new[341]	_	_
51-4	5535-5544	cathepsin	event[341]|person[342]	new[341]|giv[342]	_	_
51-5	5545-5546	B	event[341]|person[342]	new[341]|giv[342]	_	_
51-6	5547-5550	may	_	_	_	_
51-7	5551-5553	be	_	_	_	_
51-8	5554-5567	bidirectional	_	_	_	_
51-9	5568-5569	.	_	_	_	_

#Text=It promotes the degradation of the integrity of the environment of the tumor directly or through intermediate mediators such as uPA , MMPs , or plasmin .
52-1	5570-5572	It	abstract	giv	_	_
52-2	5573-5581	promotes	_	_	_	_
52-3	5582-5585	the	event[344]	new[344]	_	_
52-4	5586-5597	degradation	event[344]	new[344]	_	_
52-5	5598-5600	of	event[344]	new[344]	_	_
52-6	5601-5604	the	event[344]|abstract[345]	new[344]|new[345]	_	_
52-7	5605-5614	integrity	event[344]|abstract[345]	new[344]|new[345]	_	_
52-8	5615-5617	of	event[344]|abstract[345]	new[344]|new[345]	_	_
52-9	5618-5621	the	event[344]|abstract[345]|abstract[346]	new[344]|new[345]|new[346]	_	_
52-10	5622-5633	environment	event[344]|abstract[345]|abstract[346]	new[344]|new[345]|new[346]	_	_
52-11	5634-5636	of	event[344]|abstract[345]|abstract[346]	new[344]|new[345]|new[346]	_	_
52-12	5637-5640	the	event[344]|abstract[345]|abstract[346]|object[347]	new[344]|new[345]|new[346]|giv[347]	_	_
52-13	5641-5646	tumor	event[344]|abstract[345]|abstract[346]|object[347]	new[344]|new[345]|new[346]|giv[347]	_	_
52-14	5647-5655	directly	_	_	_	_
52-15	5656-5658	or	_	_	_	_
52-16	5659-5666	through	_	_	_	_
52-17	5667-5679	intermediate	person[348]	new[348]	_	_
52-18	5680-5689	mediators	person[348]	new[348]	_	_
52-19	5690-5694	such	person[348]	new[348]	_	_
52-20	5695-5697	as	person[348]	new[348]	_	_
52-21	5698-5701	uPA	person[348]|abstract	new[348]|giv	_	_
52-22	5702-5703	,	person[348]	new[348]	_	_
52-23	5704-5708	MMPs	person[348]|abstract	new[348]|giv	_	_
52-24	5709-5710	,	person[348]	new[348]	_	_
52-25	5711-5713	or	person[348]	new[348]	_	_
52-26	5714-5721	plasmin	person[348]|substance	new[348]|new	_	_
52-27	5722-5723	.	_	_	_	_
